#USA #Chicago #Seegene #CURECA™ #STAgora™

Seegene Unveils Innovative Technologies for Molecular Diagnostics at ADLM 2025

In a significant advancement for molecular diagnostics, Seegene Inc., a global leader in the field, showcased two groundbreaking technologies, CURECA™ and STAgora™, during the ADLM 2025 conference held in Chicago from July 29 to 31. These innovations mark a pivotal step towards fully automated testing and real-time data analysis, with a vision to enhance laboratory efficiency and disease detection accuracy.

Introducing CURECA™

The highlight of Seegene's presentation was CURECA™, the world's first fully unattended automated PCR system. Unlike existing molecular testing systems that still require skilled personnel for routine manual processes, CURECA™ promises to fully automate every single step of the PCR testing process, including the traditionally labor-intensive sample preparation phase. This automation is seen as crucial in driving efficiency and scalability within laboratories.

Key features of CURECA™ include:

• - Continuous Operation: Designed to function round-the-clock, minimizing the risk of human error and ensuring quick turnaround times for test results.
• - Sample Versatility: The dedicated CURECA™ Prep module can process a range of sample types such as urine, blood, sputum, and stool, tackling one of the major barriers in laboratory automation.
• - End-to-End PCR Process: From sample loading to nucleic acid extraction, amplification, and results analysis, CURECA™ automates the entire PCR workflow without the need for manual intervention.

Seegene aims to tailor CURECA™ to fit different laboratory sizes and workflows, enhancing adaptability in various testing environments. Furthermore, the company sees potential expansion of CURECA™ into other testing domains, such as clinical chemistry and immunodiagnostics, as it continues to develop comprehensive automation solutions.

Real-Time Data Analysis with STAgora™

Complementing CURECA™, STAgora™ represents Seegene's latest effort in real-time data processing for PCR testing. This platform is designed to provide laboratories with a comprehensive context for optimizing diagnostic procedures and offers over 40 analytical tools. Key functionalities include:

• - Infection Trend Monitoring: Track the evolution of infections and monitor positive results at hospital levels to facilitate timely responses.
• - Multi-Pathogen Analysis: Analyze patterns of current infections involving multiple pathogens for a more nuanced understanding of disease landscapes.
• - Integrated Data Sharing: Unlike traditional data repositories, STAgora™ allows facilities to create their own statistical datasets and compare aggregated data across institutions, enhancing collaborative efforts in infection tracking.

Anonymized and formatted according to institutions’ requirements, data shared via STAgora™ supports secure exchanges of information, contributing to faster and more informed decision-making processes.

A Vision for a Disease-Free World

During the press conference held on July 30, Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, emphasized that the introduction of CURECA™ and STAgora™ signifies a major stride towards the company's long-term vision of achieving a “disease-free world.” He reiterated the importance of these technologies in overcoming the challenges of molecular diagnostics, significantly improving workflow efficiency and enabling laboratories to leverage diagnostic data effectively.

Experts at the ADLM 2025 conference expressed substantial interest in these technologies. Jamel Giuma, CEO of JTG Consulting Group, noted that CURECA™ stands out as one of the most innovative solutions he has encountered at multiple ADLM events over the years, predicting it will ease laboratory workloads and boost overall operational efficiency.

Dr. Chun concluded, stating, “Just as smartphones and electric vehicles have transformed their respective industries, we believe these technologies will redefine the possibilities of diagnostic testing, help laboratories worldwide achieve true automation, harness the value of diagnostic data, and ultimately contribute to creating a world without diseases.”

_Disclaimer: CURECA™ and STAgora™, showcased at ADLM 2025, are in pre-commercial development and have not yet been approved for clinical diagnostic use in any jurisdiction._